Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Stemcell United Ltd. ( (AU:BP8) ) is now available.
BPH Global Ltd has advanced its collaboration with Indonesia’s National Research and Innovation Agency, BRIN, to Stage 2, signing a cooperation agreement and detailed terms of reference via its Indonesian subsidiary. The deal marks the first project-specific implementation under an earlier memorandum and positions BPH Global to leverage Indonesian research capabilities in seaweed-derived bioactive compounds.
Stage 2 will focus on developing fucoidan extraction technology and a fucoidan-based powdered supplement prototype for food and beverage use, with a prototype targeted within about three months. The project, valued at roughly A$20,800 and jointly funded through BPH cash outlays and BRIN in-kind lab services, is expected to establish domestic fucoidan production capability and, if successful, pave the way for technology licensing discussions and a Stage 3 commercialisation phase.
More about Stemcell United Ltd.
BPH Global Ltd is an ASX-listed commercial seaweed supply and export company focused on developing value-added marine bioindustry products. Through its Indonesian subsidiary, PT BPH Global Indonesia, the company is expanding into functional food and nutraceutical applications, targeting fucoidan-based ingredients for food, beverage and cosmetic markets.
Current Market Cap: A$4.71M
See more data about BP8 stock on TipRanks’ Stock Analysis page.